The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease

The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease

We examined the effect of atorvastatin (and placebo) on tumour necrosis factor (TNF)α, soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble intercellular cell adhesion molecule-1 (sICAM-1) in patients with type 2 diabetes without prior cardiovascular disease (CVD) and investigated whether...

Full description

Bibliographic Details
Main Authors:	Soedamah-Muthu, S, Charlton-Menys, V, Bao, W, Schalkwijk, C, Da Stehouwer, C, Colhoun, H, Betteridge, D, Durrington, P, Hitman, G, Neil, H, Livingstone, S, Fuller, J, Demicco, D, Preston, G
Format:	Journal article
Language:	English
Published:	2011

Similar Items

Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
by: Colhoun, H, et al.
Published: (2009)

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
by: Colhoun, H, et al.
Published: (2004)

Erratum: Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: The Collaborative Atorvastatin Diabetes Study (CARDS)
by: Charlton-Menys, V, et al.
Published: (2009)

Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS).
by: Raikou, M, et al.
Published: (2007)

Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS).
by: Charlton-Menys, V, et al.
Published: (2009)

Effect of atorvastatin in patients 65 years of age with type 2 diabetes: Subgroup analysis from the collaborative atorvastatin diabetes study (CARDS)
by: DeMicco, D, et al.
Published: (2005)

Safety of atorvastatin in the collaborative AtoRvastatin diabetes study (CARDS)
by: Newman, C, et al.
Published: (2006)

C-reactive Protein and Amyloid A as Predictors of Cardiovascular Events in Type 2 Diabetes in CARDS
by: Charlton-Menys, V, et al.
Published: (2009)

Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS).
by: Charlton-Menys, V, et al.
Published: (2009)

The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS).
by: Newman, C, et al.
Published: (2008)

Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).
by: Colhoun, H, et al.
Published: (2005)

Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS).
by: Hitman, G, et al.
Published: (2007)

Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
by: Neil, H, et al.
Published: (2006)

Effect of atorvastatin on stroke in the collaborative atorvastatin diabetes study (CARDS): Factors predictive of the risk of stroke
by: Newman, C, et al.
Published: (2005)

Change in Lp-PLA2 With Risk Change on Statin Therapy in the Collaborative Atorvastatin Diabetes Study (CARDS)
by: Betteridge, D, et al.
Published: (2009)

The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.
by: Soedamah-Muthu, S, et al.
Published: (2003)

Effect of atorvastatin on stroke in patients with type 2 diabetes: factors predicting the risk of stroke in the Collaborative Atorvastatin Diabetes Study (CARDS)
by: Hitman, G, et al.
Published: (2005)

Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes.
by: Thomason, M, et al.
Published: (2004)

Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial.
by: Colhoun, H, et al.
Published: (2011)

Cost-effectiveness of atorvastatin (10mg) in patients with type 2 diabetes without coronary heart disease: CARDS trial analysis and extrapolation
by: Raikou, M, et al.
Published: (2005)

Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes.
by: Colhoun, H, et al.
Published: (2002)

Avascular tumour dynamics and necrosis
by: Please, C, et al.
Published: (1999)

Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes
by: Deedwania, PC, et al.
Published: (2016)

Tumour necrosis factor.
by: Van Der Merwe, P
Published: (1988)

Structure of tumour necrosis factor.
by: Jones, E, et al.
Published: (1989)

Tumour dynamics and necrosis: surface tension and stability.
by: Landman, K, et al.
Published: (2001)

Relationship between atorvastatin dose and the harm caused by torcetrapib
by: Philip J. Barter, et al.
Published: (2012-11-01)

Status report of lipid-lowering trials in diabetes.
by: Betteridge, D, et al.
Published: (2000)

Increased C-reactive protein levels in overweight and obese women taking exogenous hormones: the United Kingdom Women's Heart Study (UKWHS).
by: Kwok, S, et al.
Published: (2009)

The effects of pressure on chondrocyte tumour necrosis factor receptor expression.
by: Westacott, C, et al.
Published: (2002)

The severity of ankylosing spondylitis and responses to anti-tumour necrosis factor biologics are not influenced by the tumour necrosis factor receptor polymorphism incriminated in multiple sclerosis
by: Watts, L, et al.
Published: (2018)

Stimulators of tumour necrosis factor production released by damaged erythrocytes.
by: Bate, C, et al.
Published: (1994)

The three-dimensional structure of tumour necrosis factor.
by: Jones, E, et al.
Published: (1990)

Relationship of High‐Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin
by: Kwok Leung Ong, et al.
Published: (2018-01-01)

Polymorphisms in tumour necrosis factor (TNF) are associated with risk of bladder cancer and grade of tumour at presentation.
by: Marsh, H, et al.
Published: (2003)

MicroRNA 146a is associated with diabetic complications in type 1 diabetic patients from the EURODIAB PCS
by: Federica Barutta, et al.
Published: (2021-11-01)

Tumour necrosis factor-alpha gene polymorphisms and Alzheimer's disease.
by: Culpan, D, et al.
Published: (2003)

Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis.
by: Mukhtyar, C, et al.
Published: (2005)

Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment
by: Hye Kyung Hyun, et al.
Published: (2022-03-01)

A Study of Single Nucleotide Polymorphisms of Tumour Necrosis Factor α-1031 And Tumour Necrosis Factor β+ 252 in Chronic Rhinosinusitis
by: Khairunnisak Misron, et al.
Published: (2017-09-01)